Clinical Data Sanofi says drug for rare disease AATD tops standard care PharmaphorumAfter a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.Rare DiseaseRead full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx. Rare Disease Read full story Post navigation Previous: VERTANICAL’s VER-01 gains FDA breakthrough status for low back painNext: European study shows inequality in access to new medicines Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
